Back to News
Navamedic ASA acquires innovative antibiotic product for hospital use in the Nordic region
28th November, 2022
Back to News
28th November, 2022
Clindamycin is a well-established antibiotic used in treatment of severe infections, including staphylococcal bone and joint infections, chronic sinusitis and infections of the lower respiratory tract. The primary benefits of this ready-to-use packaging are a reduction in medication errors, the reduced risk of contamination, storage at ambient temperature, as well as nurse time saving and a reduction of waste.
“With our efficient market access and strong local competence, we launch and strive to enhance the value of products and brands, and this acquisition demonstrates how we continue to build assets of owned products. Over the recent months we have made a string of new product launches, partnerships and acquisitions, all bringing us closer to our NOK 1 billion revenue target in the mid- to long-term“, says Kathrine Gamborg Andreassen, CEO of Navamedic ASA.
The Clindamycin ready-to-administer bags have been on the market in Norway, Sweden and Denmark since 2020 under the label of Villerton (owned by ACS Dobfar), mainly being sold through national and regional hospital tenders. The transfer of the marketing authorizations will be initiated within short, and the product is expected to be on the market under the Navamedic label from early 2023.